Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health, nutrient content claims final rule interim authority granted in FDA reform bill.

This article was originally published in The Tan Sheet

Executive Summary

FDA HEALTH, NUTRIENT CONTENT CLAIMS FINAL RULE INTERIM AUTHORITY would be permitted within parameters outlined in the conference report on S 830, the FDA Modernization Act, passed by the House and Senate Nov. 9. Under the bill, FDA may make proposed food claims regulations effective upon publication, pending public comment and publication of a final regulation, when HHS "determines that it is necessary...to improve consumer access to important dietary information and to ban or modify a claim in a prompt fashion," according to an "explanatory statement" accompanying the report.

You may also be interested in...



FDA Urged To Revise Manufacturing Reg To Increase Flexibility For OTCs

Drug firms have more flexibility changing production protocols for over-the-counter drugs than pharmaceuticals, but the industry would benefit if FDA regulations allowed supplements for OTC products' chemistry, manufacturing and controls to be done without prior approval, an industry representative says

FDA Urged To Revise Manufacturing Reg To Increase Flexibility For OTCs

Drug firms have more flexibility changing production protocols for over-the-counter drugs than pharmaceuticals, but the industry would benefit if FDA regulations allowed supplements for OTC products' chemistry, manufacturing and controls to be done without prior approval, an industry representative says

FDA Urged To Revise Manufacturing Reg To Increase Flexibility For OTCs

Drug firms have more flexibility changing production protocols for over-the-counter drugs than pharmaceuticals, but the industry would benefit if FDA regulations allowed supplements for OTC products' chemistry, manufacturing and controls to be done without prior approval, an industry representative says

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel